Vanguard Asset Management
ALNY icon

Vanguard Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Vanguard Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$77.6M Buy
257,710
+38,475
+18% +$11.6M 0.05% 309
2026
Q1 		$72.5M Buy
+219,235
New +$74.6M 0.06% 279

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Asset Management's ALNY Position: Q2 2026 in Review

Vanguard Asset Management increased its Alnylam Pharmaceuticals (ALNY) stake by 18% in Q2 2026, buying an estimated $11.6M and bringing the position to 257,710 shares worth $77.6M. The position accounts for 0.05% of the portfolio, ranked #309.

Vanguard Asset Management first reported a position in ALNY in Q1 2026 and has held it in 2 quarters since. 733 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Vanguard Asset Management held 257,710 shares of Alnylam Pharmaceuticals worth $77.6M as of Q2 2026.
  • Vanguard Asset Management bought 38,475 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $11.6M.
  • Alnylam Pharmaceuticals made up 0.05% of Vanguard Asset Management's portfolio in Q2 2026, its #309 holding.
  • Vanguard Asset Management first reported a position in Alnylam Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 733 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.